Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus

European Journal of Endocrinology

Volumn 161, Issue 3, 2009, Pages 391-395

  Li, Ke ^a   Li, Ng ^a   Yang, Mengliu ^a   Zong, Haihong ^b   Liu, Hua ^c   Yang, Gangyi ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; FIBROBLAST GROWTH FACTOR 21; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; FEMALE; GLYCEMIC CONTROL; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSS-SECTIONAL STUDY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGED; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 70349234490     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0335     Document Type: Article

References (16)

1. Nishimura T, Nakatake Y, Konishi M & Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochimica et Biophysica Acta 2000 1492 203-206. (Pubitemid 30349198)
2. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR & Shanafelt AB. FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation 2005 115 1627-1635.
3. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS & Xu A. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008 57 1246-1253.
4. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI & Petersen KF. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002 51 797-802. (Pubitemid 34760191)
5. Ciaraldi TP, Kong AP, Chu NV, Kim DD, Baxi S, Loviscach M, Plodkowski R, Reitz R, Caulfield M, Mudaliar S & Henry RR. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes 2002 51 30-36. (Pubitemid 34517976)
6. Wang H, Qiang L & Farmer SR. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Molecular and Cellular Biology 2008 28 188-200.
7. Moyers JS, Shiyanova TL, Mehrbod F, Dunbar JD, Noblitt TW, Otto KA, Reifel-Miller A & Kharitonenkov A. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARg signaling. Journal of Cellular Physiology 2007 210 1-6. (Pubitemid 44904695)
8. Muise ES, Azzolina B, Kuo DW, El-Sherbeini M, Tan Y, Yuan X, Mu J, Thompson JR, Berger JP & Wong KK. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Molecular Pharmacology 2008 74 403-412.
9. Alberti KG & Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabetic Medicine 1998 15 539-553.
10. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB & Etgen GJ. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007 1487 74-81. (Pubitemid 46143178)
11. Garvey WT, Maianu L, Huecksteadt TP, Birnbaum MJ, Molina JM & Ciaraldi TP. Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity. Journal of Clinical Investigation 1991 87 1072-1081.
12. Chen WW, Li L, Yang GY, Li K, Qi XY, Zhu W, Tang Y, Liu H & Boden G. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes mellitus. Experimental and Clinical Endocrinology and Diabetes 2008 116 65-68. (Pubitemid 351270911)
13. Li L, Yang G, Ning H, Yang M, Liu H & Chen W. Plasma FGF-21 levels in type 2 diabetic patients with ketosis. Diabetes Research and Clinical Practice 2008 82 209-213.
14. Gälman C, Lundåsen T, Kharitonenkov A, Bina HA, Eriksson M, Hafström I, Dahlin M, Amark P, Angelin B & Rudling M. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARα activation in man. Cell Metabolism 2008 8 169-174.
15. Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, Kimura M, Asada M, Komi-Kuramochi A, Oka S & Imamura T. βKlotho is required for FGF21 signaling through FGFR1c and FGFR3c. Molecular Endocrinology 2008 22 1006-1014.
16. Kharitonenkov A, Dunbar JD, Bina HA, Bright S, Moyers JS, Zhang C, Ding L, Micanovic R, Mehrbod SF, Knierman MD, Hale JE, Coskun T & Shanafelt AB. FGF-21/FGF-21 receptor interaction and activation is determined by βKlotho. Journal of Cellular Physiology 2008 215 1-7. (Pubitemid 351363185)